Mecasermin is recombinant IGF-1 studied in children with growth disorders. Those clinical outcomes cannot establish muscle-building efficacy or safety in healthy adults.
Key points
- Randomized growth research measured height velocity in children, not adult performance.
- The hormone's effects on glucose regulation are relevant to safety.
- Claims involving unregulated IGF-1 products are outside the clinical evidence base.
What the literature shows
Midyett and colleagues reported first-year results from a randomized trial of recombinant IGF-1 in short children with low IGF-1. Growth velocity improved in the studied pediatric group; that outcome is not an adult hypertrophy endpoint.
A review of mecasermin for severe primary IGF-1 deficiency describes clinical experience in a narrow indication. Neither paper supports extrapolating benefits to healthy lifters.
What remains unknown
- There is no comparable randomized evidence of net benefit for physique goals in healthy adults.
- Long-term risk under non-prescribed, mixed-drug exposure is not established.
Safety and monitoring implications
- IGF-1 can affect blood glucose; symptoms suggestive of low blood sugar warrant prompt medical attention.
- Treat growth-disorder dosing and monitoring as specialist medicine, not a template for performance use.
Cited literature
- 1.Midyett LK, Rogol AD, Van Meter QL, et al. (2010). Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. Journal of Clinical Endocrinology & Metabolism. Find on PubMed
- 2.Cappa M, Fintini D, Brufani C. (2009). Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Therapeutics and Clinical Risk Management. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying IGF-1 / mecasermin in Australia: what to check first
APEDRA does not sell IGF-1 / mecasermin or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.